NASDAQ:SMED - Nasdaq - US8200171010 - Common Stock - Currency: USD
NASDAQ:SMED (8/22/2022, 8:00:03 PM)
8.75
+0.01 (+0.11%)
The current stock price of SMED is 8.75 USD. In the past month the price increased by 1.39%. In the past year, price decreased by -7.99%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 11.03 | 82.59B | ||
CVS | CVS HEALTH CORP | 11.74 | 80.09B | ||
LH | LABCORP HOLDINGS INC | 17.36 | 21.10B | ||
DGX | QUEST DIAGNOSTICS INC | 19.47 | 19.50B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.87 | 13.67B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 147.98 | 12.11B | ||
DVA | DAVITA INC | 14.99 | 11.68B | ||
HIMS | HIMS & HERS HEALTH INC | 109.98 | 10.57B | ||
CHE | CHEMED CORP | 24 | 8.24B | ||
CRVL | CORVEL CORP | 25.89 | 5.56B | ||
OPCH | OPTION CARE HEALTH INC | 26.82 | 5.43B | ||
GH | GUARDANT HEALTH INC | N/A | 5.37B |
Sharps Compliance Corp. engages in the provision of healthcare waste management services including medical, pharmaceutical, and hazardous. The company is headquartered in Houston, Texas and currently employs 190 full-time employees. The firm's services includes medical, pharmaceutical and hazardous for small and medium quantity generators. The firm's lead products are the Sharps Recovery System and MedSafe Medication Disposal System. The Sharps Recovery System is a comprehensive medical waste management mailback solution used in all markets due to its availability. The MedSafe solution meets the immediate needs of an increasing community risk associated with unused, ultimate-user, medications. The firm also offers its route-based pick-up services in approximately 37 state regions of the South, Southeast, Southwest, Midwest and Northeast portions of the United States.
SHARPS COMPLIANCE CORP
Ste 500, 9220 Kirby Drive
Houston TEXAS 77054 US
CEO: David P. Tusa
Employees: 190
Phone: 17134320300.0
The current stock price of SMED is 8.75 USD. The price increased by 0.11% in the last trading session.
The exchange symbol of SHARPS COMPLIANCE CORP is SMED and it is listed on the Nasdaq exchange.
SMED stock is listed on the Nasdaq exchange.
9 analysts have analysed SMED and the average price target is 7.52 USD. This implies a price decrease of -14.03% is expected in the next year compared to the current price of 8.75. Check the SHARPS COMPLIANCE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SHARPS COMPLIANCE CORP (SMED) has a market capitalization of 170.01M USD. This makes SMED a Micro Cap stock.
SHARPS COMPLIANCE CORP (SMED) currently has 190 employees.
SHARPS COMPLIANCE CORP (SMED) has a support level at 8.71 and a resistance level at 8.76. Check the full technical report for a detailed analysis of SMED support and resistance levels.
The Revenue of SHARPS COMPLIANCE CORP (SMED) is expected to decline by -19.46% in the next year. Check the estimates tab for more information on the SMED EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SMED does not pay a dividend.
SHARPS COMPLIANCE CORP (SMED) will report earnings on 2022-09-13, before the market open.
The PE ratio for SHARPS COMPLIANCE CORP (SMED) is 46.05. This is based on the reported non-GAAP earnings per share of 0.19 and the current share price of 8.75 USD. Check the full fundamental report for a full analysis of the valuation metrics for SMED.
ChartMill assigns a technical rating of 8 / 10 to SMED. When comparing the yearly performance of all stocks, SMED is one of the better performing stocks in the market, outperforming 98.19% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to SMED. SMED has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months SMED reported a non-GAAP Earnings per Share(EPS) of 0.19. The EPS decreased by -67.24% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3.25% | ||
ROA | 2.89% | ||
ROE | 4.19% | ||
Debt/Equity | 0.06 |
ChartMill assigns a Buy % Consensus number of 49% to SMED. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -96.71% and a revenue growth -19.46% for SMED